We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+36.75%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.05B
AUM Growth
+$452M
Cap. Flow
+$364M
Cap. Flow %
34.66%
Top 10 Hldgs %
71.51%
Holding
46
New
14
Increased
15
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$244M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$45.9M
3
AGEN
Agenus
AGEN
+$22.6M
4
ARWR icon
Arrowhead Research
ARWR
+$18M
5
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$17.4M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$14.5M
3
OSUR icon
OraSure Technologies
OSUR
+$14.4M
4
ATRA icon
Atara Biotherapeutics
ATRA
+$10.1M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.07M

Sector Composition

Rank Sector Weight
1 Healthcare 93.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APYX icon
26
Apyx Medical
APYX
$174M
$5.74M 0.55%
1,931,948
+179,337
+10% +$462K
NVAX icon
27
Novavax
NVAX
$1.27B
$5.73M 0.54%
+136,325
New +$5.48M
ODT
28
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$5.3M 0.5%
274,544
-23,011
-8% -$543K
KA
29
DELISTED
Kineta, Inc. Common Stock
KA
$5.25M 0.5%
7,892
-2,822
-26% -$1.7M
SLDB icon
30
Solid Biosciences
SLDB
$859M
$4.61M 0.44%
+45,051
New +$15.2M
CDNA icon
31
CareDx
CDNA
$2.35B
$4.47M 0.43%
+560,600
New +$3.46M
QTTB icon
32
Q32 Bio
QTTB
$490M
$4.21M 0.4%
+12,500
New +$4.2M
ARGX icon
33
argenx
ARGX
$54.3B
$2.05M 0.19%
25,457
+197
+0.8% +$14.9K
OSUR icon
34
OraSure Technologies
OSUR
$286M
$1.98M 0.19%
117,291
-761,161
-87% -$14.4M
ELDN icon
35
Eledon Pharmaceuticals
ELDN
$266M
$1.51M 0.14%
+16,667
New +$1.23M
ADVM
36
DELISTED
Adverum Biotechnologies
ADVM
$1.02M 0.1%
+17,521
New +$1.09M
MOTS
37
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$531K 0.05%
+395
New +$556K
ATRA icon
38
Atara Biotherapeutics
ATRA
$76.9M
– –
-22,245
Closed -$10.1M
BCRX icon
39
BioCryst Pharmaceuticals
BCRX
$2.31B
– –
-3,372,674
Closed -$16.6M
TCMD icon
40
Tactile Systems Technology
TCMD
$676M
– –
-210,366
Closed -$6.1M
RVNC
41
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-23,038
Closed -$824K
ZYNE
42
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-202,859
Closed -$2.54M
FPRX
43
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-100,377
Closed -$2.2M
OXFD
44
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-375,792
Closed -$5.25M
SRTSW
45
DELISTED
Sensus Healthcare, Inc. Warrant expiring on 06/08/2020
SRTSW
– –
-151,400
Closed -$98K
1
2

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q1 2018 Portfolio in Review

As of Q1 2018, RTW Investments held 46 positions worth $1.05B, up 75% from $599M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

RTW Investments deployed $364M of net new capital in Q1 2018, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Rocket Pharmaceuticals: 14,969,744 shares worth $258M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $14.5M trimmed.

  • RTW Investments's largest Q1 2018 buy was Rocket Pharmaceuticals: 14,969,744 shares worth $258M.
  • RTW Investments added most to Agenus in Q1 2018, an estimated $22.6M increase.
  • RTW Investments's biggest Q1 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $14.5M.
  • RTW Investments fully exited BioCryst Pharmaceuticals in Q1 2018, selling an estimated $16.6M.
  • RTW Investments's ten largest holdings make up 72% of its $1.05B portfolio in Q1 2018.
  • RTW Investments opened 14 new positions and closed 8 in Q1 2018.
  • RTW Investments's portfolio value rose 75% quarter-over-quarter to $1.05B.

Based on RTW Investments's 13F filing for Q1 2018, filed 14 May 2018.